Cargando…
Challenges of international oncology trial collaboration—a call to action
International collaboration in oncology trials has the potential to enhance clinical trial activity by expediting the recruitment of large patient populations, testing treatments in diverse populations and facilitating the study of rare tumours or specific molecular subtypes. However, a number of ch...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889481/ https://www.ncbi.nlm.nih.gov/pubmed/31378784 http://dx.doi.org/10.1038/s41416-019-0532-4 |
_version_ | 1783475426883010560 |
---|---|
author | Tang, Monica Joensuu, Heikki Simes, Robert J. Price, Timothy J. Yip, Sonia Hague, Wendy Sjoquist, Katrin M. Zalcberg, John |
author_facet | Tang, Monica Joensuu, Heikki Simes, Robert J. Price, Timothy J. Yip, Sonia Hague, Wendy Sjoquist, Katrin M. Zalcberg, John |
author_sort | Tang, Monica |
collection | PubMed |
description | International collaboration in oncology trials has the potential to enhance clinical trial activity by expediting the recruitment of large patient populations, testing treatments in diverse populations and facilitating the study of rare tumours or specific molecular subtypes. However, a number of challenges continue to hinder the efficient and productive conduct of both commercial and non-commercial international clinical trials. These challenges include complex and burdensome regulatory requirements, the high cost of conducting trials, and logistical challenges associated with ethics review, drug supply and biospecimen collection and management. We propose solutions to promote oncology trial collaboration, such as regulatory reform, harmonisation of trial initiation and management processes and greater recognition and funding of academic (non-commercial) clinical trials. It is only through coordinated effort and leadership from researchers, regulators and those responsible for health systems that the full potential of international trial collaboration can be realised. |
format | Online Article Text |
id | pubmed-6889481 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-68894812020-08-05 Challenges of international oncology trial collaboration—a call to action Tang, Monica Joensuu, Heikki Simes, Robert J. Price, Timothy J. Yip, Sonia Hague, Wendy Sjoquist, Katrin M. Zalcberg, John Br J Cancer Review Article International collaboration in oncology trials has the potential to enhance clinical trial activity by expediting the recruitment of large patient populations, testing treatments in diverse populations and facilitating the study of rare tumours or specific molecular subtypes. However, a number of challenges continue to hinder the efficient and productive conduct of both commercial and non-commercial international clinical trials. These challenges include complex and burdensome regulatory requirements, the high cost of conducting trials, and logistical challenges associated with ethics review, drug supply and biospecimen collection and management. We propose solutions to promote oncology trial collaboration, such as regulatory reform, harmonisation of trial initiation and management processes and greater recognition and funding of academic (non-commercial) clinical trials. It is only through coordinated effort and leadership from researchers, regulators and those responsible for health systems that the full potential of international trial collaboration can be realised. Nature Publishing Group UK 2019-08-05 2019-10-01 /pmc/articles/PMC6889481/ /pubmed/31378784 http://dx.doi.org/10.1038/s41416-019-0532-4 Text en © The Author(s), under exclusive licence to Cancer Research UK 2019 https://creativecommons.org/licenses/by/4.0/This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0). |
spellingShingle | Review Article Tang, Monica Joensuu, Heikki Simes, Robert J. Price, Timothy J. Yip, Sonia Hague, Wendy Sjoquist, Katrin M. Zalcberg, John Challenges of international oncology trial collaboration—a call to action |
title | Challenges of international oncology trial collaboration—a call to action |
title_full | Challenges of international oncology trial collaboration—a call to action |
title_fullStr | Challenges of international oncology trial collaboration—a call to action |
title_full_unstemmed | Challenges of international oncology trial collaboration—a call to action |
title_short | Challenges of international oncology trial collaboration—a call to action |
title_sort | challenges of international oncology trial collaboration—a call to action |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889481/ https://www.ncbi.nlm.nih.gov/pubmed/31378784 http://dx.doi.org/10.1038/s41416-019-0532-4 |
work_keys_str_mv | AT tangmonica challengesofinternationaloncologytrialcollaborationacalltoaction AT joensuuheikki challengesofinternationaloncologytrialcollaborationacalltoaction AT simesrobertj challengesofinternationaloncologytrialcollaborationacalltoaction AT pricetimothyj challengesofinternationaloncologytrialcollaborationacalltoaction AT yipsonia challengesofinternationaloncologytrialcollaborationacalltoaction AT haguewendy challengesofinternationaloncologytrialcollaborationacalltoaction AT sjoquistkatrinm challengesofinternationaloncologytrialcollaborationacalltoaction AT zalcbergjohn challengesofinternationaloncologytrialcollaborationacalltoaction |